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Macrolides is effective therapy in patients with cystic fibrosis (CF). We describe a girl with CF given long-term azithromycin who died of
rapidly progressive lung disease. She was found to have rising titers of mycoplasma serology, suggesting a possible causative role of a
resistant mycoplasma infection. Mycoplasma infection should be considered in CF patients who are deteriorating, even if they are being
treated with macrolides, to which these organisms are usually susceptible.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Keywords: Rapidly progressive lung disease; Cystic fibrosis; Azithromycin; Mycoplasma infection1. Introduction
Cystic fibrosis (CF) is the most common autosomal
recessive disease among Caucasian population. It has been
reported among almost all ethnic groups including Arabs
[1]. Recently, the cystic fibrosis transmembrane regulator
(CFTR) gene mutation I1234V on exon 19 has been
identified as the main genotype of CF among large kindred
of Bedwens from Qatar [2].
The macrolide antibiotics have been of interest in CF for
more than their well-established antibacterial properties [3].
This interest started after observing dramatic improvements
with the use of low dose erythromycin in diffuse panbron-
chiolitis, a disease very similar to CF occurring in middle-
aged people from the Far East especially Japan. Recently,
the macrolide azithromycin has been studied in a random-
ized, placebo-controlled crossover trial in children with CF1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.11.002
Abbreviations: FEV 1, forced expiratory volume in 1 second; FVC,
forced vital capacity; FEF25–75%, forced expiratory flow between 25–75%
of flow–volume curve.
T Corresponding author.[4]. Subjects who received azithromycin showed significant
clinical improvement [4]. In another study, azithromycin
therapy was evaluated in 60 adults with CF. The azithro-
mycin group had better quality of life, maintained better
pulmonary function, had fewer courses of intravenous
antibiotic use and had lower CRP as compared with the
placebo group [5]. Based on these studies, their use has been
advocated in CF.
We report on a girl with CF who despite being treated
with azithromycin for about 8 months, who developed
severe progressive lung disease, with evidence suggestive of
persistent infection with Mycoplasma pneumoniae.2. Case report
SH was an 18-year-old Arabian girl from Qatar who was
diagnosed with CF at age 8 years when she presented with
recurrent pulmonary infections. She had two elevated sweat
chloride test levels (68 and 87 mmol/L). Her genotype was
confirmed to be homozygous for I1234V on exon 19.
She was pancreatic insufficient and was maintained
on pancreatic enzymes replacement therapy. At the times 4 (2005) 71–73ed by Elsevier B.V. All rights reserved.
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FEV1=83%, FEF25–75%=74% predicted) (Fig. 1). She was
started on azithromycin 250 mg orally once a day in January
2002. At that point her spirometric measures were:
FVC=63%, FEV1=65% and FEF25–75%=54% predicted.
Initially, she did well but five months later she was ad-
mitted with an acute pulmonary exacerbation. Her weight
was below the 5% for age with a BMI of 14; she
had advanced clubbing. Her pulmonary function testing
showed a sharp drop in spirometry to FVC=43%, FEV1
41% and FEF25–75%=30% predicted. Her sputum grew
mucoid Pseudomonas aeruginosa, Staphylococcus aureus
and Haemophilus influenza. All of these bacteria were
sensitive to the antibiotic regimen that she was receiving
(namely: ceftazidime, gentamicine and cloxacillin). At that
point mycoplasma antibody titre was 1:1280 (positive) she
was started on clarythromycin and azithromycin was
discontinued.
Patient’s serum was tested using serodia Myco II
(Fujirebio Inc., Tokyo, Japan) particle-agglutination test
kit for detection of anti-M. pneumoniae antibody [6]. The
kit uses artificial gelatin particles, sensitized with cell
membrane components of M. pneumoniae (Mac strain).
The test is based on the principle that sensitized particles
are agglutinated by the presence of antibody to M.
pneumoniae in patient serum. Colored artificial carrier is
used which produces more clear-cut and easy-to-read
agglutination patterns compared with hemagglutination
patterns. Positive and negative controls are included in
each run. The end antibody titer is determined as the final
dilution giving positive pattern. Specimen showing pos-
itive at 1:40 dilution or more with sensitized particles is
interpreted as positive.
She improved slightly after 3 weeks on clarythromycin
but her spirometry was unchanged (FVC=44%, FEV1=48%
and FEF25–75%=34% predicted) and she became oxygen
dependant at home. She was readmitted a month later in

















Fig. 1. Deterioration in FEV1, FVC and FEF25–75% over time.spirometry at that point showed a further drop (FVC=30%,
FEV1=28%, FEF25–75%=14% predicted) (Fig. 1). A repeat
mycoplasma antibody titre was positive at 1:6200. Her
sputum continued to grow the same microorganisms but was
not specifically cultured for mycoplasma species (myco-
plasma cultures are not done in our laboratory). She was re-
started on clarythromycin, however, without significant
improvement. She continued to deteriorate and died a week
later.3. Discussion
We report this case for two reasons; firstly, although one
possible reason for beneficial effect of macrolides has been
proposed to be treatment of occult atypical infection, she
developed Mycoplasma Pneumonia during the course of
macrolide therapy. We assume that her high mycoplasma
(particle agglutination) titer was due to a persistent and
recent mycoplasma infection. The test insert claims 86%
sensitivity and 83% specificity. Some other organisms might
cross-react with mycoplasma CFT e.g. Legionella, Q-fever
and Chlamydia infections; the particle agglutination test has
much less cross reactivity problem than other serological
tests. However, it must be acknowledged that specific
testing for some of these other infections might have been
helpful. The fact that her titres increased on her second
admission argues for a recent and possibly persistent
mycoplasma infection.
Suspicion of M. pneumoniae infection is usually based
on serological studies (either ELISA or CFT), however, to
confirm the diagnosis, mycoplasma culture is necessary.
Most laboratories–including that of our institute–do not
routinely culture for M. pneumoniae. In addition, methods
for PCR diagnosis M. pneumoniae are yet to be validated
and are not generally available.
Macrolide resistance in M. pneumoniae is not well
described and the mechanism is unknown. The benefit from
long-term treatment of CF patients with azithromycin is an
empirical observation that becomes evident after several
months’ therapy [4]. The mechanism of this benefit is
unknown and hypotheses include an anti-inflammatory
mechanism. The development of resistant strains of M.
pneumoniae because of long-term use of macrolides is
unknown. Although we do not have antibiotic susceptibil-
ities, it seems likely that a macrolide resistant strain of M.
pneumoniae was selected by this therapy; to our knowledge,
a similar case has not been reported before.
The second reason for reporting this case is to highlight
the possible role of non-typical CF organisms in the
deteriorating patient. The long-term use of macrolide
antibiotics has resulted in significant improvements in
patients with diffuse panbronchiolitis. They are currently
recommended for CF patients not doing well on conven-
tional treatments based on large clinical trials [4,5] and yet
unpublished USCFF data (personal communication). Empir-
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bronchiectasis secondary to a variety of etiologies.
Although SH was chronically colonized with the busualQ
CF bacteria in her sputum, we speculate that development of
resistant strains of mycoplasma species might have played a
significant role in her rapid deterioration and death. In
support of this view is the fact that the bacteria isolated from
sputum were all sensitive to the antibiotic regimen that she
was treated with. In addition, her sputa failed to grow any of
the more recently described bnew CF organismsb [atypical
mycobacteria, B. Cepaca, Alcaligenes] that might explain
the late clinical deterioration.
Although macrolide antibiotics have proved to be
effective in cases of diffuse panbronchiolitis and are
advocated in CF, the possible adverse effects of long-term
use in CF need to be further studied.References
[1] Desgeorges M, Megarbane A, Guittard C, et al. Cystic fibrosis in
Lebanon: distribution of CFTR mutations among Arab communities.
Hum Genet 1997 (Aug.);100(2):279–83.
[2] Abdul Wahab A, Al Thani G, Dawod ST, et al. Heterogeneity of the
cystic fibrosis phenotype in a large kindred family in Qatar with cystic
fibrosis mutation (I1234V). J Trop Pediatr 2001;47:110–2.
[3] Bush A. Macrolides in cystic fibrosis. J Cyst Fibros 2002;1:S11–2.
[4] Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term
azithromycin in children with cystic fibrosis: randomized placebo-
controlled crossover trial. Lancet 2002;360:978–84.
[5] Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with
azithromycin on disease parameters in cystic fibrosis: a randomized
trial. Thorax 2002;57:212–6.
[6] Taylor P. Evaluation of an indirect Hemagglutination kit for the rapid
serological diagnosis of Mycoplasma pneumoniae infections. J Clin
Pathol 1979;32:280.
